Skip to main content

Advertisement

ADVERTISEMENT

AMP 2022

Quality of Life Improvement After PVI: Insights From the LIBERTY 360 Study

Dr. Eric Secemsky
Eric Secemsky, MD, MSc, FACC, FAHA, FSCAI, FSVM

Written by Cynthia Laufenberg, MA

Presented by Eric Secemsky, MD, MSc, FACC, FAHA, FSCAI, FSVM

Thursday’s sessions kicked off with “Atherectomy: Controversial or Essential?” Included was a presentation by Eric Secemsky, MD, MSc, FACC, FAHA, FSCAI, FSVM, Director of Vascular Intervention at Beth Israel Deaconess Medical Center in Boston, entitled “Quality of Life Improvement after PVI: Insights From the LIBERTY 360 Study.”

Dr. Secemsky began by discussing the fact that peripheral arterial disease (PAD) is associated with high morbidity and mortality, as well as a poor quality of life (QoL). He then asked two questions: “How do we improve care for our PAD patients?” and “How do we move toward outcomes that are meaningful to patients?”

To help answer these questions, Dr. Secemsky shared insights from the LIBERTY 360 QoL study, which enrolled 1,080 patients (included both claudicants and CLI; all underwent endovascular peripheral vascular intervention (PVI). QoL outcomes were measured at 30 days, 12 months, and 36 months. QoL measures persistently improved after PVI. “Patient-reported outcome measures are critical to improve patient-centric peripheral vascular care,” Dr. Secemsky said. Comorbidities and baseline health status are predictive of 30-day, 1-year, and 3-year outcomes.

Slide

 

Dr. Secemsky concluded by emphasizing the importance of involving patients in decision-making. Broadening evidence-based treatment options, creating individualized protection tools, and incorporating patient-centered outcomes will lead to optimal patient care.

Slide

 


Advertisement

Advertisement

Advertisement